Marijn C. Visschedijk

3.4k total citations · 1 hit paper
53 papers, 1.3k citations indexed

About

Marijn C. Visschedijk is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Marijn C. Visschedijk has authored 53 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Genetics, 25 papers in Epidemiology and 20 papers in Surgery. Recurrent topics in Marijn C. Visschedijk's work include Inflammatory Bowel Disease (33 papers), Microscopic Colitis (19 papers) and Helicobacter pylori-related gastroenterology studies (13 papers). Marijn C. Visschedijk is often cited by papers focused on Inflammatory Bowel Disease (33 papers), Microscopic Colitis (19 papers) and Helicobacter pylori-related gastroenterology studies (13 papers). Marijn C. Visschedijk collaborates with scholars based in Netherlands, United States and Denmark. Marijn C. Visschedijk's co-authors include Rinse K. Weersma, Eleonora A. Festen, Gerard Dijkstra, Hendrik M. van Dullemen, Cisca Wijmenga, Lieke M. Spekhorst, Arnau Vich Vila, Lude Franke, Jingyuan Fu and Floris Imhann and has published in prestigious journals such as Nature Communications, Gastroenterology and PLoS ONE.

In The Last Decade

Marijn C. Visschedijk

51 papers receiving 1.3k citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease

2016 576 citations Floris Imhann, Arnau Vich Vila et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marijn C. Visschedijk Netherlands	15	656	573	348	309	205	53	1.3k
Akihiko Oka Japan	22	514 0.8×	345 0.6×	306 0.9×	379 1.2×	276 1.3×	76	1.4k
Takehide Fujimoto Japan	13	628 1.0×	380 0.7×	270 0.8×	211 0.7×	236 1.2×	30	1.2k
Charlotte Hedin Sweden	21	848 1.3×	716 1.2×	358 1.0×	405 1.3×	397 1.9×	58	1.8k
Shabnam Shahrokh Iran	22	529 0.8×	317 0.6×	258 0.7×	224 0.7×	163 0.8×	93	1.2k
Rebeca Santaolalla United States	19	445 0.7×	314 0.5×	351 1.0×	312 1.0×	333 1.6×	31	1.3k
J. Cosnes France	6	808 1.2×	511 0.9×	339 1.0×	217 0.7×	181 0.9×	10	1.3k
Paul A. Rufo United States	16	350 0.5×	507 0.9×	333 1.0×	361 1.2×	156 0.8×	36	1.3k
Srinivasan Pugazhendhi India	18	463 0.7×	279 0.5×	227 0.7×	235 0.8×	98 0.5×	37	1000
Christopher D. Packey United States	9	767 1.2×	270 0.5×	185 0.5×	174 0.6×	159 0.8×	17	1.2k
Zhaohua Shen China	19	1.2k 1.8×	372 0.6×	259 0.7×	175 0.6×	173 0.8×	31	1.7k

Countries citing papers authored by Marijn C. Visschedijk

Since Specialization

Citations

This map shows the geographic impact of Marijn C. Visschedijk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marijn C. Visschedijk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marijn C. Visschedijk more than expected).

Fields of papers citing papers by Marijn C. Visschedijk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marijn C. Visschedijk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marijn C. Visschedijk. The network helps show where Marijn C. Visschedijk may publish in the future.

Co-authorship network of co-authors of Marijn C. Visschedijk

This figure shows the co-authorship network connecting the top 25 collaborators of Marijn C. Visschedijk. A scholar is included among the top collaborators of Marijn C. Visschedijk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marijn C. Visschedijk. Marijn C. Visschedijk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gorpas, Dimitris, et al.. (2025). P0944 Fluorescently labelled adalimumab to visualise drug targeting in Inflammatory Bowel Disease: a safety, feasibility and dose-finding study. Journal of Crohn s and Colitis. 19(Supplement_1). i1765–i1766. 1 indexed citations

Fleer, Joke, Ans Smink, Marijn C. Visschedijk, et al.. (2024). Long-term treatment outcomes of mindfulness-based cognitive therapy for fatigue in patients with inflammatory bowel disease: Results of a randomized controlled trial. Journal of Psychosomatic Research. 187. 111949–111949. 2 indexed citations

Dijkstra, Gerard, et al.. (2024). Vaginal delivery in women with perianal Crohn's disease: why not?. AJOG Global Reports. 4(2). 100333–100333. 6 indexed citations

Vogl, Thomas, Sergio Andreu‐Sánchez, Shelley Klompus, et al.. (2024). P193 Fatigued patients with Inflammatory Bowel Disease exhibit distinct systemic antibody epitope repertoires. Journal of Crohn s and Colitis. 18(Supplement_1). i502–i503. 1 indexed citations

Hu, Shixian, Arno R. Bourgonje, Ranko Gaćeša, et al.. (2024). Mucosal host-microbe interactions associate with clinical phenotypes in inflammatory bowel disease. Nature Communications. 15(1). 1470–1470. 35 indexed citations

Heijnen, Marieke, Jeroen Maljaars, F van Schaik, et al.. (2024). P964 Vedolizumab trough concentrations during subcutaneous treatment in patients with inflammatory bowel diseases. Journal of Crohn s and Colitis. 18(Supplement_1). i1741–i1742. 1 indexed citations

Bourgonje, Arno R., Marian Bulthuis, Lukas J.A.C. Hawinkels, et al.. (2023). Hepcidin and Iron Status in Patients With Inflammatory Bowel Disease Undergoing Induction Therapy With Vedolizumab or Infliximab. Inflammatory Bowel Diseases. 29(8). 1272–1284. 11 indexed citations

Steenhuis, Maurice, Floris C. Loeff, Daan J. Touw, et al.. (2023). Clinical Validation of a Capillary Blood Home-Based Self-Sampling Technique for Monitoring of Infliximab, Vedolizumab, and C-Reactive Protein Concentrations in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 30(3). 325–335. 8 indexed citations

Blokzijl, Hans, et al.. (2023). Immune Checkpoint Inhibitor-related Pancreatitis: A Case Series, Review of the Literature and an Expert Opinion. Journal of Immunotherapy. 46(7). 271–275. 15 indexed citations

10.

Bourgonje, Arno R., Eleonora A. Festen, Hendrik M. van Dullemen, et al.. (2022). Use of Tumor Necrosis Factor-α Antagonists Is Associated With Attenuated IgG Antibody Response Against SARS-CoV-2 in Vaccinated Patients With Inflammatory Bowel Disease. Frontiers in Immunology. 13. 920333–920333. 2 indexed citations

11.

Bourgonje, Arno R., M.A. Karsdal, Hendrik M. van Dullemen, et al.. (2022). Serological Biomarkers of Intestinal Collagen Turnover Identify Early Response to Infliximab Therapy in Patients With Crohn’s Disease. Frontiers in Medicine. 9. 933872–933872. 9 indexed citations

12.

Bourgonje, Arno R., Shixian Hu, Hendrik M. van Dullemen, et al.. (2022). Proteomic analyses do not reveal subclinical inflammation in fatigued patients with clinically quiescent inflammatory bowel disease. Scientific Reports. 12(1). 14581–14581. 4 indexed citations

13.

Biemans, Vince, Frank Hoentjen, Nanne K.H. de Boer, et al.. (2021). Ustekinuma b for Crohn’s Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study. Journal of Crohn s and Colitis. 15(11). 1920–1930. 26 indexed citations

14.

Kats‐Ugurlu, Gürsah, Remco J. Renken, Henk J. Buikema, et al.. (2021). Immune checkpoint inhibitor treatment induces colitis with heavy infiltration of CD8 + T cells and an infiltration pattern that resembles ulcerative colitis. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 479(6). 1119–1129. 16 indexed citations

15.

Sloot, Kimberley W. J. van der, Michiel Voskuil, Hendrik M. van Dullemen, et al.. (2020). Environmental factors associated with biological use and surgery in inflammatory bowel disease. Journal of Gastroenterology and Hepatology. 36(4). 1022–1034. 4 indexed citations

16.

Imhann, Floris, K. Joeri van der Velde, Rudi Alberts, et al.. (2019). The 1000IBD project: multi-omics data of 1000 inflammatory bowel disease patients; data release 1. BMC Gastroenterology. 19(1). 5–5. 62 indexed citations

17.

Visschedijk, Marijn C., et al.. (2017). Colon ischemia: Right-sided colon involvement has a different presentation, etiology and worse outcome. A large retrospective cohort study in histology proven patients. Best Practice & Research Clinical Gastroenterology. 31(1). 111–117. 11 indexed citations

18.

Kolkman, Jeroen J., et al.. (2013). Tu2002 Right Versus Left-Sided Ischemic Colitis: Different Presentation and Worse Prognosis; A Study in a Cohort of 474 Patients. Gastroenterology. 144(5). S–901. 2 indexed citations

19.

Fransén, Karin, Marijn C. Visschedijk, Suzanne van Sommeren, et al.. (2010). Analysis of SNPs with an effect on gene expression identifies UBE2L3 and BCL3 as potential new risk genes for Crohn's disease. Human Molecular Genetics. 19(17). 3482–3488. 77 indexed citations

20.

Sommeren, Suzanne van, Marijn C. Visschedijk, Eleonora A. Festen, et al.. (2010). HNF4α and CDH1 are associated with ulcerative colitis in a Dutch cohort. Inflammatory Bowel Diseases. 17(8). 1714–1718. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact